Breaking News, Promotions & Moves

BioCentriq Names New CEO

Appoints Syed T. Husain as its new Chief Executive Officer (CEO), and as a member of the Board of Directors.

Author Image

By: Charlie Sternberg

Associate Editor

BioCentriq, a cell therapy contract development and manufacturing organization (CDMO), has appointed Syed T. Husain as its new Chief Executive Officer (CEO), and as a member of the Board of Directors.   Husain offers extensive expertise in CDMO development and manufacturing services, with a deep understanding of the cell and gene therapy supply and value chains. His experience spans the entire drug development and commercialization lifecycle, including over 20 years of strategic management, le...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters